D'Orazio & Associates, Inc. Puma Biotechnology, Inc. Transaction History
D'Orazio & Associates, Inc.
- $738 Million
- Q3 2025
A detailed history of D'Orazio & Associates, Inc. transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, D'Orazio & Associates, Inc. holds 31,933 shares of PBYI stock, worth $158,068. This represents 0.02% of its overall portfolio holdings.
Number of Shares
31,933
Previous 15,027
112.5%
Holding current value
$158,068
Previous $51,000
219.61%
% of portfolio
0.02%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding PBYI
# of Institutions
135Shares Held
35.2MCall Options Held
264KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$20.4 Million11.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.69MShares$18.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$17.7 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.15MShares$10.6 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA2.05MShares$10.2 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $226M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...